Amgen announced preliminary Phase 3 results showing dazodalibep met key efficacy goals in Sjögren’s disease, a common autoimmune condition with no approved targeted therapy. The fusion protein, acquired as part of Amgen’s big Horizon Therapeutics deal, reduced disease severity in the trial data released. The readout strengthens Amgen’s late-stage pipeline built from Horizon assets and raises the prospect of a first-in-class Sjögren’s treatment. It also sets up increased competitive focus among companies targeting other immune pathways in dry-eye and systemic Sjögren’s. For investors, the Sjögren’s win signals continued integration of Horizon’s pipeline into Amgen’s development engine, with further milestones likely tied to trial completion details and regulatory timelines.